Titan Pharmaceuticals Inc
NASDAQ:TTNP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.145
5.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Titan Pharmaceuticals Inc
Cash from Operating Activities
Titan Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
Cash from Operating Activities
-$2.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$24.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$16.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
25%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$13.1B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$17.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$16.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
17%
|
|
Titan Pharmaceuticals Inc
Glance View
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in South San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
See Also
What is Titan Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-3.9m
USD
Based on the financial report for Dec 31, 2024, Titan Pharmaceuticals Inc's Cash from Operating Activities amounts to -3.9m USD.
What is Titan Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
4%
Over the last year, the Cash from Operating Activities growth was 45%. The average annual Cash from Operating Activities growth rates for Titan Pharmaceuticals Inc have been 21% over the past three years , 24% over the past five years , and 4% over the past ten years .